BioVie (NASDAQ:BIVI) Announces Quarterly Earnings Results

BioVie (NASDAQ:BIVI) announced its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share for the quarter, Zacks reports.

BioVie Stock Performance

BIVI opened at $1.73 on Thursday. BioVie has a 1-year low of $1.04 and a 1-year high of $33.10. The firm has a 50-day moving average price of $2.15 and a two-hundred day moving average price of $2.29.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.